COVID Treatment: Ayush Ministry gives nod to use of AYUSH 64 & Kabasura Kudineer
New Delhi: The Union Ministry of Ayush gave a nod to the use of two polyherbal ayurvedic drugs Ayush 64 and Siddha drug Kabasura Kudineer for treatment of mild to moderate Covid-19 infection.
Many clinical and observational studies have been undertaken to understand the role of AYUSH interventions in the mitigation and management of Covid-19. Various studies were carried out on AYUSH-64, an Ayurvedic formulation developed by the Central Council for Research in Ayurvedic Sciences (CCRAS) and Kabasura Kudineer, a classical Siddha formulation.
A statement claimed that the Ministry of Ayush-Council of Scientific and Industrial Research collaboration has recently completed a robust multi-centre clinical trial to evaluate the safety and efficacy of AYUSH 64 in the management of mild to moderate Covid-19 patients.
“Kabasura Kudineer, a Siddha medicine was also subjected to clinical trials for studying the efficacy in Covid-19 patients by Central Council for Research in Siddha (CCRS) under Ministry of Ayush and is also found useful in the treatment of mild to moderate Covid-19 infection,” it said.
The Ministry has also set up an Interdisciplinary Committee for Inclusion of Ayurveda and Yoga Interventions in the ‘National Clinical Management Protocol: Covid-19’, which was chaired by Dr V M Katoch, former Director-General ICMR.
“Based on the encouraging results of AYUSH-64 and Kabasura Kudineer in the management of asymptomatic, mild to moderate Covid-19 as an adjunct to standard care, the Ministry of Ayush is launching this nationwide campaign for the distribution of AYUSH-64 and Kabasura Kudineer today so that the Covid -19 patients in home isolation may be benefited with Ayush systems of medicines,” the statement said.